Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients

Dylan Fortman,Maria G. Pazan Avellan,Drew Hurd,Marc Schwartz,Howard Dubner,Corey Hewitt,Samantha Berton,Scarlett Ernst,Amy Rose,Hong Wangd, Hassane Zarour,Diwakar Davar
DOI: https://doi.org/10.1097/cmr.0000000000000871
2023-02-24
Melanoma Research
Abstract:Fecal microbiota transplant (FMT) hasbeen commonlyused to treat recurrent Clostridium difficile infections (rCDI), a hospital-acquired infectiontypically treated with prolonged courses of antibiotics, which maintain and exacerbate intestinal dysbiosis [ 1 ]. FMT restores normal gut ecology, and in this context is well-tolerated and efficacious with cure rates of 85% in rCDI [ 2–5 ].
dermatology,oncology,medicine, research & experimental
What problem does this paper attempt to address?